STAREE Trial Proves Statins Cut Heart Risk in Healthy Adults Over 70

For years, prescribing statins to healthy older adults without established cardiovascular disease has been controversial, with limited randomized evidence and concerns about side effects outweighing uncertain benefits. The STAREE trial, presented at the European Society of Cardiology meeting in Munich and simultaneously published in the New England Journal of Medicine, now changes that picture substantially.

The trial enrolled adults aged 70 and older who had no history of cardiovascular disease, diabetes, dementia, or other major life-limiting conditions. Participants were randomized to atorvastatin 40mg daily or placebo and followed for six years. The primary composite cardiovascular endpoint — death from cardiovascular causes, nonfatal heart attack or stroke, or coronary revascularization — occurred at a rate of 10.9 per 1,000 person-years in the statin group versus 15.5 in the placebo group, a hazard ratio of 0.70 (95% CI 0.61–0.82), representing a 30% relative risk reduction.

Importantly, this benefit was consistent across subgroups defined by age bracket (70–74 vs older), LDL cholesterol level, blood pressure, BMI, and kidney function. The effects persisted despite real-world complications including treatment crossovers and adherence challenges, suggesting the true benefit may be even larger under ideal conditions.

However, statins did not significantly improve disability-free survival — the composite of all-cause death, dementia, or persistent physical disability — with a hazard ratio of 0.94 (95% CI 0.84–1.05). This nuance is important: cardiovascular protection was clear, but broader healthspan benefits remain unproven in this population.

On safety, overall serious adverse events were identical between groups at 2.7%. Small but notable excesses appeared in musculoskeletal events (1.1% vs 0.9%), hepatobiliary events (1.4% vs 0.3%), and diabetes-related events (1.1% vs 0.7%). These modest risks should be weighed individually. The findings are expected to push guideline-makers toward stronger statin recommendations for healthy older adults, a population previously underserved by primary prevention evidence.